AMO-01 is under clinical development by AMO Pharma and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect AMO-01’s likelihood of approval (LoA) and phase transition for Epilepsy took place on 24 Jun 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their AMO-01 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
AMO-01 (TLN-4601) is under development for the treatment of Phelan-McDermid syndrome (PMS) and co-morbid epilepsy. The drug candidate is a small molecule. It is administered by the intravenous route which acts by targeting Ras-extracellular signal-regulated kinase pathway (Ras-ERK) and peripheral benzodiazepine receptor (PBR).
It was also under development for the treatment of advanced cancer including glioblastoma multiforme, high-grade glioma, colorectal cancer, lung cancer, breast cancer, ovarian cancer pancreatic cancer and prostate cancer. The drug candidate was also under development for the treatment of fragile X syndrome.
AMO Pharma overview
AMO Pharma is a biopharmaceutical company that develops novel treatments for serious and debilitating diseases. The company offers pipeline product portfolio such as AMO-01, and AMO-02. Its AMO-01 is being developed for the treatment of autism and intellectual disabilities. It is an inhibitor of the ras-extracellular signal-regulated kinase pathway (Ras-ERK). AMO Pharma offers AMO-02 which is used for the treatment of myotonic dystrophy, CNS, neuromuscular and oncology indications, among others. It is an inhibitor of glycogen synthase kinase 3 beta. The company provides target therapy areas such as central nervous system disorders, neuromuscular, and Steinert’s disease. It also has operations in the US and the UK. AMO Pharma is headquartered in London, the UK.
Quick View AMO-01 LOA Data
|Highest Development Stage|